Dorzolamide

Introduction Overview

Generic Name

dorzolamide

Brand Name

Trusopt Ocumeter, Trusopt Ocumeter Plus

Dosage Form

ophthalmic solution (eye drops)

Drug Class

Ophthalmic glaucoma agents; Carbonic anhydrase inhibitor

Pharmacokinetics

Absorption:
Dorzolamide ophthalmic solution is administered topically via eye drops. Systemic absorption occurs through the conjunctiva and nasolacrimal duct after ophthalmic administration. Despite local administration, measurable plasma concentrations have been detected, though they are markedly lower than those achieved by oral carbonic anhydrase inhibitors. The extent of systemic absorption is influenced by factors such as tear film turnover, presence of contact lenses, and ocular surface integrity. After instillation, peak plasma concentrations usually occur within a few hours. Local ocular absorption is efficient, providing therapeutic levels within the aqueous humor to reduce intraocular pressure.

Distribution:
Once absorbed systemically, dorzolamide demonstrates moderate plasma protein binding, primarily to erythrocytes where it readily partitions given its affinity for carbonic anhydrase in red blood cells. The drug distributes extensively in ocular tissues, concentrating in the ciliary body where aqueous humor production takes place. The lipophilic nature facilitates penetration through ocular membranes. However, the volume of distribution is relatively small systemically due to localized administration. Ocular distribution allows dorzolamide to exert its pharmacodynamic effects by inhibiting carbonic anhydrase in the ciliary processes.

Metabolism:
Dorzolamide undergoes minimal hepatic metabolism. It is metabolized primarily by cytochrome P450 enzymes in the liver, with metabolites excreted in the urine. The inactive metabolites have no clinical pharmacological activity. The limited systemic exposure reduces the risk of systemic side effects associated with oral carbonic anhydrase inhibitors. Because of minimal metabolism, drug-drug interactions via hepatic enzyme induction or inhibition are limited but should still be monitored, especially when co-administered with other agents metabolized by P450 enzymes.

Elimination:
Elimination of dorzolamide occurs predominantly through renal excretion of unchanged drug and its metabolites. The systemic half-life is prolonged due to extensive erythrocyte binding, resulting in a terminal elimination half-life of approximately 4 months, reflecting slow release from erythrocytes. However, given the topical route, the functional ocular pharmacokinetics are defined more by local clearance mechanisms, including aqueous humor turnover. The prolonged systemic half-life does not usually impact dosing frequency but is a consideration in patients with renal impairment, as accumulation could theoretically occur. Overall, elimination is relatively slow but clinically effective in maintaining intraocular pressure reduction with three-times-daily dosing.

Dosage Forms

Available Dosage Forms:
- Ophthalmic solution (eye drops)

Dosages for Adults and Adolescents:
- For treatment of open-angle glaucoma or ocular hypertension: Instill one drop in the affected eye(s) three times daily.

Specific Patient Populations:
- Pediatrics: Safety and efficacy have not demonstrated specific pediatric problems but dosage should be determined by the physician.
- Geriatrics: No geriatric-specific problems identified; generally well tolerated.
- Patients with sulfonamide allergy should use with caution due to risk of hypersensitivity reactions.
- Patients with severe hepatic or renal impairment should use with caution; dose adjustments and close monitoring are advised.

Clinical Guidelines:
Dorzolamide solution is designed for topical ophthalmic use only. Soft contact lenses should be removed prior to administration and may be reinserted 15 minutes after dosing to avoid drug absorption by lenses. Proper aseptic technique should be observed to prevent contamination. In cases where multiple ophthalmic medications are prescribed, dosing should be spaced by at least 5 minutes between different eye drops to avoid washout effects.

Storage Instructions:
Store at room temperature away from heat, moisture, or direct light; do not freeze. Keep the bottle tightly closed and avoid contamination of the dropper tip.

Mechanism Of Action

Dorzolamide is a potent, selective carbonic anhydrase inhibitor primarily affecting the enzyme isoform II present in ocular ciliary processes. By inhibiting carbonic anhydrase, dorzolamide decreases bicarbonate ion formation from carbon dioxide and water, which is a crucial step in aqueous humor production. The reduced bicarbonate ion concentration leads to decreased sodium and fluid transport in the ciliary epithelium, effectively lowering aqueous humor secretion and intraocular pressure (IOP).

At the cellular level, dorzolamide binds reversibly to the zinc ion within the active site of carbonic anhydrase. This binding prevents the hydration of carbon dioxide to bicarbonate and protons, disrupting the physiological balance required for ion transport and fluid secretion in the ciliary body. The resultant decrease in aqueous humor production reduces elevated IOP, a central pathogenic factor in open-angle glaucoma and ocular hypertension.

Biochemically, the inhibition of carbonic anhydrase results in altered ionic gradients and reduced osmotic flow across the ciliary epithelium. This leads to decreased volume of aqueous humor formed. Lower intraocular pressure alleviates stress on ocular structures such as the optic nerve, thereby reducing the risk of glaucomatous damage and vision loss.

Compared to systemic carbonic anhydrase inhibitors, dorzolamide’s topical application limits systemic exposure while achieving effective local concentrations in the eye. Clinical studies have demonstrated that dorzolamide significantly lowers IOP with fewer systemic adverse effects than oral agents. Its mechanism complements other glaucoma therapies, allowing additive or synergistic effects when used in combination treatments.

Pharmacological Actions

Selective inhibition of carbonic anhydrase II enzyme in ocular ciliary body
Reduction of aqueous humor secretion leading to decreased intraocular pressure
Topical antiglaucoma agent with localized ocular effects
Decreases production of bicarbonate ions, impacting sodium and fluid transport in eye
Low systemic absorption minimizing systemic adverse effects
Complementary action to beta-blockers and prostaglandin analogs used in glaucoma
Demonstrates reversible, competitive inhibition at zinc-containing active site
Exerts effects without pupillary constriction or systemic hypotension
Improves ocular hemodynamics secondary to intraocular pressure reduction
Demonstrates sustained efficacy with thrice-daily dosing regimen
May cause mild local ocular irritation as part of pharmacological profile
Does not increase aqueous humor outflow but decreases its formation

Therapeutic Or Clinical Uses

Treatment of elevated intraocular pressure due to open-angle glaucoma
Management of ocular hypertension to prevent optic nerve damage
Reduction of elevated intraocular pressure in patients intolerant or partially responsive to beta-blockers
Alternative or adjunctive therapy in combination with other glaucoma medications such as timolol
Used in pediatric patients when clinically indicated for ocular hypertension
Management of ocular hypertension in patients with contraindications to systemic carbonic anhydrase inhibitors
Maintenance therapy for chronic open-angle glaucoma patients
Pressure reduction to preserve visual field and prevent progression of glaucomatous optic neuropathy
Treatment adjunct post-ophthalmic surgery to control intraocular pressure spikes
Useful in patients with comorbidities rendering systemic agents unsuitable

Side Or Adverse Effects

Burning, stinging, or discomfort upon instillation of eye drops (common)
Itching, redness, swelling or irritation of the eye or eyelids
Dryness or excessive tearing of the eyes
Discharge from the eye including mucous or crusting
Blurred vision or changes in visual acuity
Sensitivity to light (photophobia) and increased ocular sensitivity
Bitter or unpleasant taste sensation after application
Headache and eyelid reactions such as crusting or scaling
Rare reports of systemic effects including blood in urine (hematuria)
Nausea, vomiting, or abdominal pain in rare systemic absorption cases
Skin rash, hives, or allergic skin reactions including blistering
Flashes of light and floaters indicating possible visual disturbances
Signs of serious hypersensitivity reactions including swelling of face or throat
Symptoms of overdose may include muscle cramps, numbness, seizures, or irregular heartbeat
Occasional respiratory symptoms such as cough or difficulty breathing

Precautions

Use with caution in patients with known allergy to sulfonamide drugs due to potential cross-reactivity
Monitor closely in patients with severe renal or hepatic impairment owing to altered drug elimination
Avoid use in patients with acute angle-closure glaucoma without appropriate concomitant therapy
Discontinue and consult physician if signs of ocular irritation or allergic reactions occur
Remove soft contact lenses prior to administration and wait at least 15 minutes before reinsertion
Inform healthcare provider about all concomitant medications to evaluate for interactions
Use cautiously in patients with recent eye surgery or corneal diseases to prevent exacerbation
Pregnant or breastfeeding women should weigh potential benefits against unknown risks
Ensure proper hygiene and administration technique to avoid contamination and ocular infections
Advise patients about possible transient blurred vision and avoid activities requiring clear vision until tolerance is established
Regular ophthalmologic examinations are recommended to monitor efficacy and side effects
Avoid concurrent use with other topical ocular medications without physician approval to prevent washout effect
Patients should report any unusual systemic symptoms such as fatigue, rash, or bleeding tendencies
Storage instructions must be followed to maintain medication stability and efficacy

Warnings

Possible serious allergic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis in sulfonamide hypersensitive individuals
Not studied in acute angle-closure glaucoma; may delay necessary definitive treatment
Potential for increased ocular irritation or worsening of corneal disorders in predisposed patients
Use cautiously in patients prone to ocular infections or with current bacterial keratitis
Systemic accumulation can occur in severe renal impairment leading to toxicity
Blurred vision after instillation may temporarily impair ability to perform hazardous tasks
Patients should be advised to avoid contaminating the dropper tip to prevent ocular infections
Avoid use in patients with hypersensitivity to dorzolamide or other components of the formulation
Long-term safety in pediatric patients has not been fully established; use only if clearly needed
Concomitant use with systemic carbonic anhydrase inhibitors may increase risk of metabolic acidosis
Not recommended during pregnancy unless potential benefit justifies potential risk to fetus
Patients should seek immediate medical help if signs of severe skin reactions or systemic hypersensitivity appear

Contraindication

Hypersensitivity to dorzolamide or any ingredient in the formulation
Known allergy to sulfonamide or sulfa drugs due to increased risk of cross-reactivity
Use in patients with acute angle-closure glaucoma unless in conjunction with appropriate therapy
Severe renal impairment or significant kidney disease where drug elimination may be compromised
Hypersensitivity reactions or previous severe allergic response to any carbonic anhydrase inhibitor
Use is contraindicated if eye infection is present, such as bacterial keratitis until infection is resolved
Patients with history of severe ocular surface diseases where further irritation is contraindicated
Known intolerance or idiosyncratic reactions to ophthalmic formulations containing preservatives
Avoid use in patients with a history of Quinazolines hypersensitivity as structural class caution
Contraindicated in individuals with conditions that could be exacerbated by systemic absorption such as metabolic acidosis

Drug Interactions

Concomitant use with systemic carbonic anhydrase inhibitors (e.g., acetazolamide) may increase systemic toxicity
Potential interaction with aspirin may influence dorzolamide systemic effects; cautious coadministration advised
Memantine and dorzolamide coadministration requires monitoring; pharmacodynamic interactions possible
Metformin concurrent use with dorzolamide may require renal function monitoring due to accumulation risk
Topiramate may have additive carbonic anhydrase inhibitory effects, increasing risk of metabolic acidosis
Co-administration with other ophthalmic medications requires timing separation of at least 5 minutes
No significant CYP450 enzyme interactions expected but vigilance is recommended in polypharmacy
Concomitant use with diuretics may potentiate electrolyte disturbances
Avoid combination with drugs that may increase risk of sulfonamide hypersensitivity
Potential alteration of drug absorption if applied with ophthalmic products containing preservatives
Concurrent use with nephrotoxic drugs requires careful renal monitoring
Hypokalemia risk may be increased with combined use of agents affecting electrolyte balance
Use with caution when combining with oral hypoglycemics due to altered renal clearance
Interactions with other glaucoma treatments such as beta-blockers can be complementary but require monitoring
No significant interaction with food, alcohol, or tobacco expected with topical ocular administration

Preparations Of The Drug

Trusopt Ocumeter - Ophthalmic solution
Trusopt Ocumeter Plus - Combination products with timolol (beta-blocker) ophthalmic solution
Dorzolamide hydrochloride in sterile buffered aqueous solution for topical ocular use
Preservative-containing formulations for multi-dose bottles (e.g., benzalkonium chloride)
Single-use unit dose vials available for preservative-free formulations in some markets
Formulated to a pH range compatible with ocular surface to minimize irritation
Available in standard concentrations of 2% dorzolamide ophthalmic solution
Packaging designed with tamper-evident caps and safety seals to maintain sterility
Accompanied by patient information leaflets detailing proper storage and administration
Developed as part of fixed-dose combinations with other glaucoma agents for synergistic effects
Manufactured under stringent GMP conditions with validated sterility and potency
Bottles designed to deliver precise microdroplets to facilitate accurate dosing
Stability ensured for room temperature storage with recommended shelf life post-opening
Formulations screened for ocular compatibility minimizing allergic reactions and toxicity
Available through prescription to ensure appropriate medical oversight and monitoring